ZEMAIRA®

FDA INDICATION: Zemaira is an alpha-1 proteinase inhibitor indicated for chronic augmentation and maintenance therapy in adults with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema. Package Insert

FORM: Lyophilized

DISTRIBUTOR: CSL Behring

ROUTE OF ADMINISTRATION: Intravenous

DOSAGE STRENGTH: 1 gram

DILUENT SIZE: 20 mL

DOSE: 60 mg/kg body weight administered once weekly

MIXING DEVICE: Double-ended plastic transfer device

STORAGE: When stored up to 25°C (77°F), Zemaira is stable for the period indicated by the expiration date on its label. Avoid freezing, which may damage the diluent vial.

HALF-LIFE: 5.1 (±2.4) days

OTHER WEBSITES: zemaira.com